Seed Funding for Early Stage Research

The Gastric Cancer Foundation provides early funding for projects that show promise to facilitate the development of new treatments for gastric cancer.


Total Seed Grants

Supporting Innovative New Research

Announcing 2024 Seed Grants for Early-Stage Research

We are now accepting letters of intent from researchers in the United States who are working on novel projects aimed at discovering new therapies and diagnostics for early detection of gastric cancer. Recipients will be awarded a one-time grant of up to $100,000. Up to two grants will be awarded this year.

Letters of intent should be submitted by email no later than March 29, 2024 to grants@gastriccancer.org.

View Eligibility Criteria and Deadlines

Early-stage seed funding is extremely important because it enables researchers to generate sufficient preliminary data to submit compelling and competitive applications for large grants. It is often difficult for researchers to obtain this type of support. The Gastric Cancer Foundation has made early funding a special focus of its research strategy.


Targeting TGFβ signaling in gastric cancer: A biomarker-driven approach towards clinical translation

Kishore Guda, DVM, PhD
Case Western Reserve University School of Medicine

$100,000 granted in 2023 

Targeting claudin 18.2-expressing gastric cancer using T cell antigen coupler (TAC)-T cells

Ryan Moy, MD, PhD
Columbia University Irving Medical Center

$100,000 granted in 2023 

Identifying and targeting peritoneal-specific immunosuppresive networkls in gastric cancer from patient-derived samples

Alexandra-Chloé Villani, PhD
Massachusetts General Hospital

$100,000 granted in 2023 

Pre-clinical project to evaluate the effects of SCD1 inhibition in GCK mouse stomachs and to determine whether the SCD1 inhibition can be a possible therapeutic intervention or treatment in patients with gastric dysplasia or early-stage cancer

Eunyoung Choi, PhD
Vanderbilt University Medical Center

$100,000 granted in 2022 


The Oral Commensal Bacterium Fusobacterium Nucleatum as a Potential Driver of Gastric Cancer 

Dr. Nina Salama, Ph.D.
Fred Hutchinson Cancer Research Center

$100,000 granted in 2021 


Utilization of molecular evaluation of clinically-annotated patient samples and the application of single cell RNA-sequencing to strong in vitro model systems to understand the therapeutic potential of platinum chemotherapy and PARP inhibitors in HR-deficient gastric cancer

Nilay Sethi, MD, PhD
Dana-Farber/Harvard Cancer Center

$100,000 granted in 2022 


Targeting Myeloid Cells to Enhance Immune Checkpoint Blockade in Gastric Cancer 

Dr. Timothy C. Wang, M.D
Columbia University

$100,000 granted in 2021 


Exploiting KMT2 as a Predictive Marker and Therapeutic Target in Advanced Gastric Cancer

Dr. Heinz-Josef Lenz
USC Norris Comprehensive Cancer Center

$75,000 Granted in 2020


New Targets and Therapies for Chromosomal Instability Underlying Gastric Cancer

Dr. Adam Bass
Dana-Farber Cancer Institute

$75,000 Granted in 2020


Interperitoneal Project to Develop New Therapies for Peritoneal Caricinomatosis

Dr. Jaffer Ajani
MD Anderson Cancer Center

$75,000 Granted in 2019


Study to Test Effectiveness of Combination Drug Therapy to Target Gastric Cancers with FGFR2 Defect and Prevent Drug Resistance

Dr. Hanlee Ji
Stanford Genome Technology Center

$30,104 Granted in 2019

Studying the Gastric Cancer Microenvironment Using Single Cell Genomics

Dr. Hanlee Ji
Stanford Genome Technology Center

$38,518 Granted in 2019


Use of Next-Generation DNA Sequencing Technology to Perform Whole-Genome Level Analysis on large Cohort of Individuals with Gastric Cancer

Dr. James Ford
Stanford University Medical School

$550,000 Total Grants 2010-2015

Making Strategic Investments Toward a Cure

Together, we can find a cure for gastric cancer. Support our critical research studies and patient education initiatives and find your cause for hope.